Esteemed epidemiologist: ‘We must start treating immediately’ with hydroxychloroquine

Contrary to popular politicized opinion, hydroxychloroquine can be highly effective against COVID-19, according to a seasoned epidemiology professor at the Yale School of Public Health.

The only caveats are that the much-debated drug must be administered early in the virus’s attack and, when doable, combined with the antibiotics azithromycin or doxycycline and the nutritional supplement zinc.

So maintains Harvey A. Risch, MD, PhD, whose credentials include authoring more than 300 peer-reviewed studies and holding senior positions on editorial boards at several leading scientific journals.

Risch’s opinion piece is running in Newsweek.

After summarizing evidence of hydroxychloroquine’s efficacy against COVID and contextualizing widely disseminated warnings about its potential for causing cardiac arrhythmia, Risch pleads with the public to place hard science over hot passion.

“In the future, I believe this misbegotten episode regarding hydroxychloroquine will be studied by sociologists of medicine as a classic example of how extra-scientific factors overrode clear-cut medical evidence. But for now, reality demands a clear, scientific eye on the evidence and where it points,” he writes.

“For the sake of high-risk patients, for the sake of our parents and grandparents, for the sake of the unemployed, for our economy and for our polity, especially those disproportionally affected, we must start treating immediately.”

Click here to read the whole thing.

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.